Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-10-2021 | Ionizing Radiation | Original Article

EANM position paper on the role of radiobiology in nuclear medicine

Authors: An Aerts, Uta Eberlein, Sören Holm, Roland Hustinx, Mark Konijnenberg, Lidia Strigari, Fijs W.B. van Leeuwen, Gerhard Glatting, Michael Lassmann

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2021

Executive Summary

With an increasing variety of radiopharmaceuticals for diagnostic or therapeutic nuclear medicine as valuable diagnostic or treatment option, radiobiology plays an important role in supporting optimizations. This comprises particularly safety and efficacy of radionuclide therapies, specifically tailored to each patient. As absorbed dose rates and absorbed dose distributions in space and time are very different between external irradiation and systemic radionuclide exposure, distinct radiation-induced biological responses are expected in nuclear medicine, which need to be explored. This calls for a dedicated nuclear medicine radiobiology. Radiobiology findings and absorbed dose measurements will enable an improved estimation and prediction of efficacy and adverse effects. Moreover, a better understanding on the fundamental biological mechanisms underlying tumor and normal tissue responses will help to identify predictive and prognostic biomarkers as well as biomarkers for treatment follow-up. In addition, radiobiology can form the basis for the development of radiosensitizing strategies and radioprotectant agents. Thus, EANM believes that, beyond in vitro and preclinical evaluations, radiobiology will bring important added value to clinical studies and to clinical teams. Therefore, EANM strongly supports active collaboration between radiochemists, radiopharmacists, radiobiologists, medical physicists, and physicians to foster research toward precision nuclear medicine.

EURAMED represents the European Association of Nuclear Medicine (EANM), the European Federation of Organizations for Medical Physics (EFOMP), the European Federation of Radiographer Societies (EFRS), the European Society of Radiology (ESR), and the European Society for Radiotherapy and Oncology (ESTRO).

Eberlein U, Bröer JH, Vandevoorde C, Santos P, Bardiès M, Bacher K, et al. Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine – a review. Eur J Nucl Med Mol Imaging. 2011;38:2269–81. https://doi.org/10.1007/s00259-011-1904-z.CrossRefPubMedPubMedCentral

Chawla SC, Federman N, Zhang D, Nagata K, Nuthakki S, McNitt-Gray M, et al. Estimated cumulative radiation dose from PET/CT in children with malignancies: a 5-year retrospective review. Pediatr Radiol. 2010;40:681–6. https://doi.org/10.1007/s00247-009-1434-z.CrossRefPubMed

Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O'Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16. https://doi.org/10.1007/s00259-012-2330-6.CrossRefPubMedPubMedCentral

Strigari L, Konijnenberg M, Chiesa C, Bardies M, Du Y, Gleisner KS, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1976–88. https://doi.org/10.1007/s00259-014-2824-5.CrossRefPubMed

Jia X, Guo K, Gao R, Yu Y, Yang A. Radiosensitivity-related postirradiation hypothyroidism in Graves’ disease patients. Hormones (Athens). 2019;18:267–72. https://doi.org/10.1007/s42000-019-00123-7.CrossRef

De-Colle C, Yaromina A, Hennenlotter J, Thames H, Mueller AC, Neumann T, et al. Ex vivo γH2AX radiation sensitivity assay in prostate cancer: inter-patient and intra-patient heterogeneity. Radiother Oncol. 2017;124:386–94. https://doi.org/10.1016/j.radonc.2017.08.020.CrossRefPubMed

Eberlein U, Nowak C, Bluemel C, Buck AK, Werner RA, Scherthan H, et al. DNA damage in blood lymphocytes in patients after ¹⁷⁷Lu peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2015;42:1739–49. https://doi.org/10.1007/s00259-015-3083-9.CrossRefPubMedPubMedCentral

Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C, et al. Patients resistant against PSMA-targeting α-radiation therapy often harbor mutations in DNA damage-repair-associated genes. J Nucl Med. 2020;61:683–8. https://doi.org/10.2967/jnumed.119.234559.CrossRefPubMed

Terry SYA, Nonnekens J, Aerts A, Baatout S, de Jong M, Cornelissen B, et al. Call to arms: need for radiobiology in molecular radionuclide therapy. Eur J Nucl Med Mol Imaging. 2019;46:1588–90. https://doi.org/10.1007/s00259-019-04334-3.CrossRefPubMed

10.

Morris ZS, Wang AZ, Knox SJ. The radiobiology of radiopharmaceuticals. Semin Radiat Oncol. 2021;31:20–7. https://doi.org/10.1016/j.semradonc.2020.07.002.CrossRefPubMed

11.

Verburg FA, Nonnekens J, Konijnenberg MW, de Jong M. To go where no one has gone before: the necessity of radiobiology studies for exploration beyond the limits of the “holy Gray” in radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-020-05147-5.

12.

Eberlein U, Scherthan H, Bluemel C, Peper M, Lapa C, Buck AK, et al. DNA damage in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy. J Nucl Med. 2016;57:173–9. https://doi.org/10.2967/jnumed.115.164814.CrossRefPubMed

13.

Schumann S, Eberlein U, Muhtadi R, Lassmann M, Scherthan H. DNA damage in leukocytes after internal ex-vivo irradiation of blood with the alpha-emitter Ra-223. Sci Rep. 2018;8:2286. https://doi.org/10.1038/s41598-018-20364-7.CrossRefPubMedPubMedCentral

14.

Schumann S, Scherthan H, Lapa C, Serfling S, Muhtadi R, Lassmann M, et al. DNA damage in blood leucocytes of prostate cancer patients during therapy with (¹⁷⁷)Lu-PSMA. Eur J Nucl Med Mol Imaging. 2019;46:1723–32. https://doi.org/10.1007/s00259-019-04317-4.CrossRefPubMedPubMedCentral

15.

Denoyer D, Lobachevsky P, Jackson P, Thompson M, Martin OA, Hicks RJ. Analysis of ¹⁷⁷Lu-DOTA-octreotate therapy-induced DNA damage in peripheral blood lymphocytes of patients with neuroendocrine tumors. J Nucl Med. 2015;56:505–11. https://doi.org/10.2967/jnumed.114.145581.CrossRefPubMed

16.

Schumann S, Eberlein U, Lapa C, Müller J, Serfling S, Lassmann M, et al. α-Particle-induced DNA damage tracks in peripheral blood mononuclear cells of [²²³Ra]RaCl₂-treated prostate cancer patients. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-020-05170-6.

17.

Dalm SU, Nonnekens J, Doeswijk GN, de Blois E, van Gent DC, Konijnenberg MW, et al. Comparison of the therapeutic response to treatment with a ¹⁷⁷Lu-labeled somatostatin receptor agonist and antagonist in preclinical models. J Nucl Med. 2016;57:260–5. https://doi.org/10.2967/jnumed.115.167007.CrossRefPubMed

18.

Nonnekens J, Chatalic KL, Molkenboer-Kuenen JD, Beerens CE, Bruchertseifer F, Morgenstern A, et al. ²¹³Bi-labeled prostate-specific membrane antigen-targeting agents induce DNA double-strand breaks in prostate cancer xenografts. Cancer Biother Radiopharm. 2017;32:67–73. https://doi.org/10.1089/cbr.2016.2155.CrossRefPubMed

19.

O'Neill E, Kersemans V, Allen PD, Terry SYA, Torres JB, Mosley M, et al. Imaging DNA damage repair in vivo after ¹⁷⁷Lu-DOTATATE therapy. J Nucl Med. 2020;61:743–50. https://doi.org/10.2967/jnumed.119.232934.

20.

Poty S, Mandleywala K, O'Neill E, Knight JC, Cornelissen B, Lewis JS. ⁸⁹Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. Theranostics. 2020;10:5802–14. https://doi.org/10.7150/thno.44772.

21.

Pichard A, Marcatili S, Karam J, Constanzo J, Ladjohounlou R, Courteau A, et al. The therapeutic effectiveness of ¹⁷⁷Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. Leukemia. 2020;34:1315–28. https://doi.org/10.1038/s41375-019-0677-4.

22.

Othman MFB, Verger E, Costa I, Tanapirakgul M, Cooper MS, Imberti C, et al. In vitro cytotoxicity of Auger electron-emitting [⁶⁷Ga]Ga-trastuzumab. Nucl Med Biol. 2020;80–81:57–64. https://doi.org/10.1016/j.nucmedbio.2019.12.004.

23.

Othman MF, Mitry NR, Lewington VJ, Blower PJ, Terry SY. Re-assessing gallium-67 as a therapeutic radionuclide. Nucl Med Biol. 2017;46:12–8. https://doi.org/10.1016/j.nucmedbio.2016.10.008.CrossRefPubMedPubMedCentral

24.

Hofving T, Sandblom V, Arvidsson Y, Shubbar E, Altiparmak G, Swanpalmer J, et al. ¹⁷⁷Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition. Endocr Relat Cancer. 2019;26:437–49. https://doi.org/10.1530/erc-18-0509.CrossRefPubMedPubMedCentral

25.

Chan T, O'Neill E, Habjan C, Cornelissen B. Combination strategies to improve targeted radionuclide therapy. J Nucl Med. 2020. https://doi.org/10.2967/jnumed.120.248062.

26.

Nonnekens J, van Kranenburg M, Beerens CE, Suker M, Doukas M, van Eijck CH, et al. Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib. Theranostics. 2016;6:1821–32. https://doi.org/10.7150/thno.15311.CrossRefPubMedPubMedCentral

27.

Purohit NK, Shah RG, Adant S, Hoepfner M, Shah GM, Beauregard JM. Potentiation of ¹⁷⁷Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor. Oncotarget. 2018;9:24693–706. https://doi.org/10.18632/oncotarget.25266.

28.

Cullinane C, Waldeck K, Kirby L, Rogers BE, Eu P, Tothill RW, et al. Enhancing the anti-tumour activity of ¹⁷⁷Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP. Sci Rep. 2020;10:10196. https://doi.org/10.1038/s41598-020-67199-9.

29.

Lundsten S, Spiegelberg D, Stenerlöw B, Nestor M. The HSP90 inhibitor onalespib potentiates ¹⁷⁷LuDOTATATE therapy in neuroendocrine tumor cells. Int J Oncol. 2019;55:1287–95. https://doi.org/10.3892/ijo.2019.4888.CrossRefPubMedPubMedCentral

30.

Claringbold PG, Price RA, Turner JH. Phase I–II study of radiopeptide ¹⁷⁷Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Cancer Biother Radiopharm. 2012;27:561–9. https://doi.org/10.1089/cbr.2012.1276.CrossRefPubMed

31.

Claringbold PG, Brayshaw PA, Price RA, Turner JH. Phase II study of radiopeptide ¹⁷⁷Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38:302–11. https://doi.org/10.1007/s00259-010-1631-x.CrossRefPubMed

32.

Bison SM, Haeck JC, Bol K, Koelewijn SJ, Groen HC, Melis M, et al. Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies. EJNMMI Res. 2015;5:62. https://doi.org/10.1186/s13550-015-0142-y.CrossRefPubMedPubMedCentral

33.

Spetz J, Langen B, Rudqvist N, Parris TZ, Helou K, Nilsson O, et al. Hedgehog inhibitor sonidegib potentiates ¹⁷⁷Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice. BMC Cancer. 2017;17:528. https://doi.org/10.1186/s12885-017-3524-x.CrossRefPubMedPubMedCentral

34.

Elf AK, Bernhardt P, Hofving T, Arvidsson Y, Forssell-Aronsson E, Wängberg B, et al. NAMPT inhibitor GMX1778 enhances the efficacy of ¹⁷⁷Lu-DOTATATE treatment of neuroendocrine tumors. J Nucl Med. 2017;58:288–92. https://doi.org/10.2967/jnumed.116.177584.CrossRefPubMed

35.

Lewin J, Cullinane C, Akhurst T, Waldeck K, Watkins DN, Rao A, et al. Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside. Eur J Nucl Med Mol Imaging. 2015;42:25–32. https://doi.org/10.1007/s00259-014-2888-2.CrossRefPubMed

36.

Tesson M, Rae C, Nixon C, Babich JW, Mairs RJ. Preliminary evaluation of prostate-targeted radiotherapy using ¹³¹I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs. J Pharm Pharmacol. 2016;68:912–21. https://doi.org/10.1111/jphp.12558.

37.

Corroyer-Dulmont A, Falzone N, Kersemans V, Thompson J, Allen DP, Able S, et al. Improved outcome of ¹³¹I-mIBG treatment through combination with external beam radiotherapy in the SK-N-SH mouse model of neuroblastoma. Radiother Oncol. 2017;124:488–95. https://doi.org/10.1016/j.radonc.2017.05.002.

38.

Taelman VF, Radojewski P, Marincek N, Ben-Shlomo A, Grotzky A, Olariu CI, et al. Upregulation of key molecules for targeted imaging and therapy. J Nucl Med. 2016;57:1805–10. https://doi.org/10.2967/jnumed.115.165092.CrossRefPubMed

39.

Veenstra MJ, van Koetsveld PM, Dogan F, Farrell WE, Feelders RA, Lamberts SWJ, et al. Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells. Oncotarget. 2018;9:14791–802. https://doi.org/10.18632/oncotarget.9462.CrossRefPubMed

40.

Tian L, Chen Q, Yi X, Wang G, Chen J, Ning P, et al. Radionuclide I-131 labeled albumin-paclitaxel nanoparticles for synergistic combined chemo-radioisotope therapy of cancer. Theranostics. 2017;7:614–23. https://doi.org/10.7150/thno.17381.CrossRefPubMedPubMedCentral

41.

Andersson CK, Shubbar E, Schüler E, Åkerström B, Gram M, Forssell-Aronsson EB. Recombinant α(1)-microglobulin is a potential kidney protector in ¹⁷⁷Lu-octreotate treatment of neuroendocrine tumors. J Nucl Med. 2019;60:1600–4. https://doi.org/10.2967/jnumed.118.225243.

42.

Falzone N, Lee BQ, Able S, Malcolm J, Terry S, Alayed Y, et al. Targeting micrometastases: the effect of heterogeneous radionuclide distribution on tumor control probability. J Nucl Med. 2018;60:250–8. https://doi.org/10.2967/jnumed.117.207308.CrossRef

43.

Feijtel D, Doeswijk GN, Verkaik NS, Haeck JC, Chicco D, Angotti C, et al. Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response. Theranostics. 2021;11.

44.

Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, et al. PRRT genomic signature in blood for prediction of ¹⁷⁷Lu-octreotate efficacy. Eur J Nucl Med Mol Imaging. 2018;45:1155–69. https://doi.org/10.1007/s00259-018-3967-6.CrossRefPubMedPubMedCentral

45.

Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, et al. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. Eur J Nucl Med Mol Imaging. 2020;47:895–906. https://doi.org/10.1007/s00259-019-04601-3.CrossRefPubMed

46.

Ćwikła JB, Bodei L, Kolasinska-Ćwikła A, Sankowski A, Modlin IM, Kidd M. Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy. J Clin Endocrinol Metab. 2015;100:E1437–45. https://doi.org/10.1210/jc.2015-2792.CrossRefPubMed

47.

Spetz J, Rudqvist N, Langen B, Parris TZ, Dalmo J, Schüler E, et al. Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after ¹⁷⁷Lu[Lu]-octreotate therapy. Nucl Med Biol. 2018;60:11–8. https://doi.org/10.1016/j.nucmedbio.2018.01.006.

48.

Rudqvist N, Spetz J, Schüler E, Parris TZ, Langen B, Helou K, et al. Transcriptional response to ¹³¹I exposure of rat thyroid gland. PLoS One. 2017;12:e0171797. https://doi.org/10.1371/journal.pone.0171797.

49.

Langen B, Rudqvist N, Helou K, Forssell-Aronsson E. Microarray studies on ²¹¹At administration in BALB/c nude mice indicate systemic effects on transcriptional regulation in nonthyroid tissues. J Nucl Med. 2017;58:346–53. https://doi.org/10.2967/jnumed.116.176958.CrossRefPubMed

50.

Schüler E, Rudqvist N, Parris TZ, Langen B, Helou K, Forssell-Aronsson E. Transcriptional response of kidney tissue after ¹⁷⁷Lu-octreotate administration in mice. Nucl Med Biol. 2014;41:238–47. https://doi.org/10.1016/j.nucmedbio.2013.12.001.CrossRefPubMed

51.

Chan HS, de Blois E, Morgenstern A, Bruchertseifer F, de Jong M, Breeman W, et al. In vitro comparison of ²¹³Bi- and ¹⁷⁷Lu-radiation for peptide receptor radionuclide therapy. PLoS One. 2017;12:e0181473. https://doi.org/10.1371/journal.pone.0181473.

52.

Kumar C, Jayakumar S, Pandey BN, Samuel G, Venkatesh M. Cellular and molecular effects of beta radiation from I-131 on human tumor cells: a comparison with gamma radiation. Curr Radiopharm. 2014;7:138–43. https://doi.org/10.2174/1874471007666140716115938.CrossRefPubMed

53.

Müller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1919–30. https://doi.org/10.1007/s00259-019-04345-0.CrossRefPubMedPubMedCentral

54.

Paillas S, Ladjohounlou R, Lozza C, Pichard A, Boudousq V, Jarlier M, et al. Localized irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects. Antioxid Redox Signal. 2016;25:467–84. https://doi.org/10.1089/ars.2015.6309.

55.

Ladjohounlou R, Lozza C, Pichard A, Constanzo J, Karam J, Le Fur P, et al. Drugs that modify cholesterol metabolism Alter the p38/JNK-mediated targeted and nontargeted response to alpha and auger radioimmunotherapy. Clin Cancer Res. 2019;25:4775–90. https://doi.org/10.1158/1078-0432.Ccr-18-3295.CrossRefPubMed

56.

Tamborino G, De Saint-Hubert M, Struelens L, Seoane DC, Ruigrok EAM, Aerts A, et al. Cellular dosimetry of [¹⁷⁷Lu]Lu-DOTA-[Tyr³]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity. EJNMMI Phys. 2020;7:8. https://doi.org/10.1186/s40658-020-0276-5.CrossRefPubMedPubMedCentral

57.

Alcocer-Ávila ME, Ferreira A, Quinto MA, Morgat C, Hindié E, Champion C. Radiation doses from ¹⁶¹Tb and ¹⁷⁷Lu in single tumour cells and micrometastases. EJNMMI Phys. 2020;7:33. https://doi.org/10.1186/s40658-020-00301-2.CrossRefPubMedPubMedCentral

58.

Strigari L, Benassi M, Chiesa C, Cremonesi M, Bodei L, D'Andrea M. Dosimetry in nuclear medicine therapy: radiobiology application and results. Q J Nucl Med Mol Imaging. 2011;55:205–21.PubMed

59.

Sarnelli A, Guerriero F, Botta F, Ferrari M, Strigari L, Bodei L, et al. Therapeutic schemes in ¹⁷⁷Lu and ⁹⁰Y-PRRT: radiobiological considerations. Q J Nucl Med Mol Imaging. 2017;61:216–31. https://doi.org/10.23736/s1824-4785.16.02744-8.CrossRefPubMed

60.

Hobbs RF, Howell RW, Song H, Baechler S, Sgouros G. Redefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy. Radiat Res. 2014;181:90–8. https://doi.org/10.1667/rr13483.1.CrossRefPubMedPubMedCentral

61.

Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm. 2005;20:47–51. https://doi.org/10.1089/cbr.2005.20.47.CrossRefPubMed

62.

Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, et al. MIRD pamphlet no. 20: the effect of model assumptions on kidney dosimetry and response—implications for radionuclide therapy. J Nucl Med. 2008;49:1884–99. https://doi.org/10.2967/jnumed.108.053173.CrossRefPubMed

63.

Gustafsson J, Nilsson P, Gleisner KS. On the biologically effective dose (BED)-using convolution for calculating the effects of repair: I. Analytical considerations. Phys Med Biol. 2013;58:1507–27. https://doi.org/10.1088/0031-9155/58/5/1507.CrossRefPubMed

64.

Gustafsson J, Nilsson P, Gleisner KS. On the biologically effective dose (BED)-using convolution for calculating the effects of repair: II. Numerical considerations. Phys Med Biol. 2013;58:1529–48. https://doi.org/10.1088/0031-9155/58/5/1529.CrossRefPubMed

65.

Strigari L, Sciuto R, Benassi M, Bergomi S, Nocentini S, Maini CL. A NTCP approach for estimating the outcome in radioiodine treatment of hyperthyroidism. Med Phys. 2008;35:3903–10. https://doi.org/10.1118/1.2964089.CrossRefPubMed

66.

Walrand S, Hesse M, Jamar F. Statistical and radiobiological analysis of the so-called thyroid stunning. EJNMMI Res. 2015;5:67. https://doi.org/10.1186/s13550-015-0144-9.CrossRefPubMedPubMedCentral

67.

Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2020. https://doi.org/10.1016/s2468-1253(20)30290-9.

68.

Walrand S, Hesse M, Jamar F, Lhommel R. A hepatic dose-toxicity model opening the way toward individualized radioembolization planning. J Nucl Med. 2014;55:1317–22. https://doi.org/10.2967/jnumed.113.135301.CrossRefPubMed

69.

Sundlöv A, Sjogreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, et al. Individualised ¹⁷⁷Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44:1480–9. https://doi.org/10.1007/s00259-017-3678-4.CrossRefPubMedPubMedCentral

70.

Jiménez-Franco LD, Kletting P, Beer AJ, Glatting G. Treatment planning algorithm for peptide receptor radionuclide therapy considering multiple tumor lesions and organs at risk. Med Phys. 2018;45:3516–23. https://doi.org/10.1002/mp.13049.CrossRef

71.

Mínguez P, Gustafsson J, Flux G, Gleisner KS. Biologically effective dose in fractionated molecular radiotherapy—application to treatment of neuroblastoma with ¹³¹I-mIBG. Phys Med Biol. 2016;61:2532–51. https://doi.org/10.1088/0031-9155/61/6/2532.

72.

Flux GD, Chittenden SJ, Saran F, Gaze MN. Clinical applications of dosimetry for mIBG therapy. Q J Nucl Med Mol Imaging. 2011;55:116–25.PubMed

73.

Kletting P, Thieme A, Eberhardt N, Rinscheid A, D'Alessandria C, Allmann J, et al. Modeling and predicting tumor response in radioligand therapy. J Nucl Med. 2019;60:65–70. https://doi.org/10.2967/jnumed.118.210377.CrossRefPubMed

74.

Draeger E, Sawant A, Johnstone C, Koger B, Becker S, Vujaskovic Z, et al. A dose of reality: how 20 years of incomplete physics and dosimetry reporting in radiobiology studies may have contributed to the reproducibility crisis. Int J Radiat Oncol Biol Phys. 2020;106:243–52. https://doi.org/10.1016/j.ijrobp.2019.06.2545.CrossRefPubMed

75.

Lassmann M, Chiesa C, Flux G, Bardiès M. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging. 2011;38:192–200. https://doi.org/10.1007/s00259-010-1549-3.CrossRefPubMed

76.

Castellucci P, Deandreis D, Krizsán A, Mirzaei S, Prior J, Sattler B, et al. European nuclear medicine guide. A joint publication by EANM and UEMS/EBNM 2020.

77.

Bolus NE. Basic review of radiation biology and terminology. J Nucl Med Technol. 2017;45:259–64. https://doi.org/10.2967/jnmt.117.195230.CrossRefPubMed

78.

Reisz JA, Bansal N, Qian J, Zhao W, Furdui CM. Effects of ionizing radiation on biological molecules—mechanisms of damage and emerging methods of detection. Antioxid Redox Signal. 2014;21:260–92. https://doi.org/10.1089/ars.2013.5489.CrossRefPubMedPubMedCentral

79.

Baselet B, Sonveaux P, Baatout S, Aerts A. Pathological effects of ionizing radiation: endothelial activation and dysfunction. Cell Mol Life Sci. 2019;76:699–728. https://doi.org/10.1007/s00018-018-2956-z.CrossRefPubMed

80.

Somosy Z. Radiation response of cell organelles. Micron. 2000;31:165–81. https://doi.org/10.1016/s0968-4328(99)00083-9.CrossRefPubMed

81.

McKelvey KJ, Hudson AL, Back M, Eade T, Diakos CI. Radiation, inflammation and the immune response in cancer. Mamm Genome. 2018;29:843–65. https://doi.org/10.1007/s00335-018-9777-0.CrossRefPubMedPubMedCentral

82.

Ramadan R, Baatout S, Aerts A, Leybaert L. The role of connexin proteins and their channels in radiation-induced atherosclerosis. Cell Mol Life Sci. 2021. https://doi.org/10.1007/s00018-020-03716-3.

83.

Kirsch DG, Diehn M, Kesarwala AH, Maity A, Morgan MA, Schwarz JK, et al. The future of radiobiology. J Natl Cancer Inst. 2018;110:329–40. https://doi.org/10.1093/jnci/djx231.CrossRefPubMed

84.

Shirato H, Le QT, Kobashi K, Prayongrat A, Takao S, Shimizu S, et al. Selection of external beam radiotherapy approaches for precise and accurate cancer treatment. J Radiat Res. 2018;59:i2–i10. https://doi.org/10.1093/jrr/rrx092.CrossRefPubMedPubMedCentral

85.

van Leeuwen CM, Oei AL, Crezee J, Bel A, Franken NAP, Stalpers LJA, et al. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol. 2018;13:96. https://doi.org/10.1186/s13014-018-1040-z.CrossRefPubMedPubMedCentral

86.

Pouget JP, Lozza C, Deshayes E, Boudousq V, Navarro-Teulon I. Introduction to radiobiology of targeted radionuclide therapy. Front Med (Lausanne). 2015;2:12. https://doi.org/10.3389/fmed.2015.00012.CrossRef

87.

Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19:589–608. https://doi.org/10.1038/s41573-020-0073-9.CrossRefPubMed

88.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of ¹⁷⁷Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35. https://doi.org/10.1056/NEJMoa1607427.

89.

Brabander T, Nonnekens J, Hofland J. The next generation of peptide receptor radionuclide therapy. Endocr Relat Cancer. 2019;26:C7–c11. https://doi.org/10.1530/erc-19-0186.CrossRefPubMed

90.

Feijtel D, de Jong M, Nonnekens J. Peptide receptor radionuclide therapy: looking back, looking forward. Curr Top Med Chem. 2020. https://doi.org/10.2174/1568026620666200226104652.

91.

Bodei L, Schöder H, Baum RP, Herrmann K, Strosberg J, Caplin M, et al. Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. Lancet Oncol. 2020;21:e431–e43. https://doi.org/10.1016/s1470-2045(20)30323-5.CrossRefPubMedPubMedCentral

92.

European Association of Nuclear Medicine (EANM), European Federation of Organizations for Medical Physics (EFOMP), European Federation of Radiographer Societies (ESR), European Society of Radiology (ESR), European Society for Radiotherapy and Oncology (ESTRO). Common strategic research agenda for radiation protection in medicine. Insights Imaging. 2017;8:183–97. https://doi.org/10.1007/s13244-016-0538-x.

93.

Council of the European Union. European Council Directive 2013/59/Euratom on basic safety standards for protection against the dangers arising from exposure to ionising radiation and repealing directives 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom. Off J EU. 2014;L13:1–73.

94.

Konijnenberg M, Herrmann K, Kobe C, Verburg F, Hindorf C, Hustinx R, et al. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-05038-9.

95.

May MS, Brand M, Wuest W, Anders K, Kuwert T, Prante O, et al. Induction and repair of DNA double-strand breaks in blood lymphocytes of patients undergoing ¹⁸F-FDG PET/CT examinations. Eur J Nucl Med Mol Imaging. 2012;39:1712–9. https://doi.org/10.1007/s00259-012-2201-1.CrossRefPubMed

96.

Schnarr K, Carter TF, Gillis D, Webber C, Lemon JA, Dayes I, et al. Biological response of positron emission tomography scan exposure and adaptive response in humans. Dose Response. 2015;13:1559325815611904. https://doi.org/10.1177/1559325815611904.CrossRefPubMedPubMedCentral

97.

Nautiyal A, Mondal T, Mukherjee A, Mitra D, Kaushik A, Goel HC, et al. Quantification of DNA damage in patients undergoing non-contrast and contrast enhanced whole body PET/CT investigations using comet assay and micronucleus assay. Int J Radiat Biol. 2019;95:710–9. https://doi.org/10.1080/09553002.2019.1577569.CrossRefPubMed

98.

Schmeiser HH, Muehlbauer KR, Mier W, Baranski AC, Neels O, Dimitrakopoulou-Strauss A, et al. DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay. Mutagenesis. 2019;34:239–44. https://doi.org/10.1093/mutage/gez007.CrossRefPubMedPubMedCentral

99.

Schumann S, Scherthan H, Frank T, Lapa C, Muller J, Seifert S, et al. DNA damage in blood leukocytes of prostate cancer patients undergoing PET/CT examinations with [⁶⁸Ga]Ga-PSMA I&T. Cancers (Basel). 2020;12:388. https://doi.org/10.3390/cancers12020388.CrossRef

100.

Brix G, Günther E, Rössler U, Endesfelder D, Kamp A, Beer A, et al. Double-strand breaks in lymphocyte DNA of humans exposed to [¹⁸F]fluorodeoxyglucose and the static magnetic field in PET/MRI. EJNMMI Res. 2020;10:43. https://doi.org/10.1186/s13550-020-00625-1.CrossRefPubMedPubMedCentral

101.

Rief M, Hartmann L, Geisel D, Richter F, Brenner W, Dewey M. DNA double-strand breaks in blood lymphocytes induced by two-day ^99mTc-MIBI myocardial perfusion scintigraphy. Eur Radiol. 2018;28:3075–81. https://doi.org/10.1007/s00330-017-5239-4.

102.

European Association of Nuclear Medicine, Flux G, Stokke C, (Editors). Internal Dosimetry Task Force Report. Treatment planning for molecular radiotherapy: potential and prospects. 2017.

103.

Stokke C, Gabiña PM, Solný P, Cicone F, Sandström M, Gleisner KS, et al. Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force. EJNMMI Phys. 2017;4:27. https://doi.org/10.1186/s40658-017-0194-3.CrossRefPubMedPubMedCentral

104.

Beels L, Bacher K, De Wolf D, Werbrouck J, Thierens H. Gamma-H2AX foci as a biomarker for patient X-ray exposure in pediatric cardiac catheterization: are we underestimating radiation risks? Circulation. 2009;120:1903–9. https://doi.org/10.1161/circulationaha.109.880385.CrossRefPubMed

105.

Beels L, Werbrouck J, Thierens H. Dose response and repair kinetics of gamma-H2AX foci induced by in vitro irradiation of whole blood and T-lymphocytes with X- and gamma-radiation. Int J Radiat Biol. 2010;86:760–8. https://doi.org/10.3109/09553002.2010.484479.CrossRefPubMed

106.

Beels L, Bacher K, Smeets P, Verstraete K, Vral A, Thierens H. Dose-length product of scanners correlates with DNA damage in patients undergoing contrast CT. Eur J Radiol. 2012;81:1495–9. https://doi.org/10.1016/j.ejrad.2011.04.063.CrossRefPubMed

107.

Vandevoorde C, Franck C, Bacher K, Breysem L, Smet MH, Ernst C, et al. γ-H2AX foci as in vivo effect biomarker in children emphasize the importance to minimize x-ray doses in paediatric CT imaging. Eur Radiol. 2015;25:800–11. https://doi.org/10.1007/s00330-014-3463-8.CrossRefPubMed

108.

ICRP. Publication 103: The 2007 recommendations of the International Commission of Radiological Protection. Ann ICRP. 2007;37(2–4).

109.

Doss M. Are we approaching the end of the linear no-threshold era? J Nucl Med. 2018;59:1786–93. https://doi.org/10.2967/jnumed.118.217182.CrossRefPubMed

110.

Pennington CW, Siegel JA. The linear no-threshold model of low-dose radiogenic cancer: a failed fiction. Dose Response. 2019;17:1559325818824200. https://doi.org/10.1177/1559325818824200.CrossRefPubMedPubMedCentral

111.

Bouffler S, Auvinen A, Cardis E, Durante M, Jourdain JR, Harms-Ringdahl M, et al. Strategic Research Agenda of the Multidisciplinary European Low Dose Initiative (MELODI). 2019

Title: EANM position paper on the role of radiobiology in nuclear medicine
Authors: An Aerts
Uta Eberlein
Sören Holm
Roland Hustinx
Mark Konijnenberg
Lidia Strigari
Fijs W.B. van Leeuwen
Gerhard Glatting
Michael Lassmann
Publication date: 01-10-2021
Publisher: Springer Berlin Heidelberg
Keywords: Ionizing Radiation
Radionuclide Therapy
Biomarkers
Neuroendocrine Tumor
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05345-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

EANM position paper on the role of radiobiology in nuclear medicine

Executive Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Executive Summary

Please log in to get access to this content

Other articles of this Issue 11/2021

Assessing immune response upon systemic RNA vaccination on [18F]-FDG PET/CT for COVID-19 vaccine and then for immuno-oncology?

Correction to: [18F]FDG PET radiomics to predict disease-free survival in cervical cancer: a multi-scanner/center study with external validation

Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial

High-resolution radioluminescence microscopy of FDG uptake in an engineered 3D tumor-stoma model

Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan

Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer